Where Cannabinoid Medicine Stands After Five Years of THC/CBD Spray Use
After five years of clinical use, THC/CBD oromucosal spray has confirmed efficacy for MS spasticity, while cannabinoid research has expanded into Alzheimer's, Parkinson's, Huntington's, and epilepsy.
Quick Facts
What This Study Found
This expert review assessed the state of cannabinoid therapeutics roughly five years after THC/CBD oromucosal spray (Sativex) entered clinical practice for multiple sclerosis spasticity.
For MS spasticity, clinical trials confirmed the spray's efficacy and tolerability, establishing it as the most widely used prescription cannabinoid medicine internationally. The review noted that the complexity of the endocannabinoid system is becoming better understood, with new signaling mechanisms emerging.
Beyond MS spasticity, the review cataloged active research into cannabinoids for various pain states, Alzheimer's disease, Parkinson's disease, Huntington's disease, and epilepsy. The authors emphasized that herbal cannabis contains many active ingredients, and individual cannabinoids have quite distinct biological activities requiring independent investigation.
The review called for continued characterization of individual cannabinoids in different diseases, noting that the therapeutic landscape is broader than any single cannabinoid product.
Key Numbers
THC/CBD oromucosal spray: THC:CBD ratio of 1.08:1.00. Approximately five years of clinical use across numerous countries at time of publication. Active research in pain, Alzheimer's, Parkinson's, Huntington's, and epilepsy.
How They Did This
Expert review of current data on the endocannabinoid system in relation to human diseases, focused on THC/CBD oromucosal spray as the primary clinical reference point and expanding to discuss potential future cannabinoid applications.
Why This Research Matters
This review provides a practical checkpoint on cannabinoid medicine after real-world clinical experience. The confirmed efficacy of THC/CBD spray for MS spasticity validates the therapeutic approach, while the expanding research pipeline suggests many more applications may follow.
The Bigger Picture
The success of THC/CBD spray for MS spasticity serves as a proof of concept for cannabinoid-based medicine. The expansion into neurodegenerative diseases represents a potentially transformative shift, as these conditions currently have limited treatment options.
What This Study Doesn't Tell Us
Expert review rather than systematic analysis. The neurodegenerative disease applications are still investigational. The review focuses primarily on one product (Sativex) and may not fully represent the broader cannabinoid therapeutic landscape.
Questions This Raises
- ?Will cannabinoid therapies for neurodegenerative diseases prove as effective as the MS spasticity application?
- ?Are combination cannabinoid products (like THC/CBD) generally superior to single-molecule approaches?
- ?How should different cannabinoids be matched to different diseases?
Trust & Context
- Key Stat:
- THC/CBD spray confirmed effective for MS spasticity after 5 years of clinical use
- Evidence Grade:
- Expert review drawing on clinical trial data and real-world experience. Moderate because it provides authoritative perspective but without systematic methodology.
- Study Age:
- Published in 2017.
- Original Title:
- Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?
- Published In:
- Expert review of clinical pharmacology, 10(4), 443-455 (2017)
- Authors:
- Maccarrone, Mauro(19), Maldonado, Rafael(14), Casas, Miguel(3), Henze, Thomas, Centonze, Diego
- Database ID:
- RTHC-01442
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What cannabinoid medicines are currently approved?
As of this 2017 review, THC/CBD oromucosal spray (Sativex) is the most widely used prescription cannabinoid, approved in multiple countries for MS spasticity. Clinical trials confirmed its efficacy and tolerability.
What diseases are being studied for cannabinoid treatment?
Beyond MS spasticity, active research is exploring cannabinoids for various pain conditions, Alzheimer's disease, Parkinson's disease, Huntington's disease, and epilepsy. Each disease may require different cannabinoid formulations.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01442APA
Maccarrone, Mauro; Maldonado, Rafael; Casas, Miguel; Henze, Thomas; Centonze, Diego. (2017). Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?. Expert review of clinical pharmacology, 10(4), 443-455. https://doi.org/10.1080/17512433.2017.1292849
MLA
Maccarrone, Mauro, et al. "Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?." Expert review of clinical pharmacology, 2017. https://doi.org/10.1080/17512433.2017.1292849
RethinkTHC
RethinkTHC Research Database. "Cannabinoids therapeutic use: what is our current understand..." RTHC-01442. Retrieved from https://rethinkthc.com/research/maccarrone-2017-cannabinoids-therapeutic-use-what
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.